MA41123A - Polythérapie pour le traitement du cancer - Google Patents

Polythérapie pour le traitement du cancer

Info

Publication number
MA41123A
MA41123A MA041123A MA41123A MA41123A MA 41123 A MA41123 A MA 41123A MA 041123 A MA041123 A MA 041123A MA 41123 A MA41123 A MA 41123A MA 41123 A MA41123 A MA 41123A
Authority
MA
Morocco
Prior art keywords
polytherapy
cancer treatment
cancer
treatment
Prior art date
Application number
MA041123A
Other languages
English (en)
Inventor
Austin Gurney
Timothy Charles Hoey
Wan-Ching Yen
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MA41123A publication Critical patent/MA41123A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA041123A 2014-12-02 2015-12-01 Polythérapie pour le traitement du cancer MA41123A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086435P 2014-12-02 2014-12-02
US201562210545P 2015-08-27 2015-08-27

Publications (1)

Publication Number Publication Date
MA41123A true MA41123A (fr) 2017-10-10

Family

ID=56092663

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041123A MA41123A (fr) 2014-12-02 2015-12-01 Polythérapie pour le traitement du cancer

Country Status (9)

Country Link
US (1) US20170266276A1 (fr)
EP (1) EP3226901A4 (fr)
JP (1) JP2018502833A (fr)
CN (1) CN107708731A (fr)
AU (1) AU2015358506A1 (fr)
CA (1) CA2969401A1 (fr)
MA (1) MA41123A (fr)
MX (1) MX2017006938A (fr)
WO (1) WO2016090024A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2694018T3 (es) 2007-07-02 2018-12-17 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el tratamiento y el diagnóstico del cáncer
WO2013012747A1 (fr) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Agents de fixation aux protéines rspo et leurs utilisations
CN104854132A (zh) 2012-07-13 2015-08-19 昂考梅德药品有限公司 Rspo3结合剂及其用途
CA2941030C (fr) 2014-02-28 2025-05-13 Merus N.V. Anticorps qui se lient à l'egfr et à l'erbb3
WO2016044295A1 (fr) 2014-09-16 2016-03-24 Oncomed Pharmaceuticals, Inc. Traitement de maladies fibrotiques
JP7296728B2 (ja) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
CA3035262A1 (fr) * 2016-09-16 2018-03-22 Tina Christine Lavranos Polytherapie a base d'un anticorps et d'un inhibiteur de point de controle
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
EP3625264B9 (fr) 2017-05-17 2023-10-25 Merus N.V. Combinaison d'un anticorps bispecifique erbb-2 / erbb-3 avec une therapie endocrine pour le cancer du sein
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
KR102762570B1 (ko) * 2017-12-07 2025-02-06 내셔날 헬스 리서치 인스티튜트 항-rspo3 항체
US12115230B2 (en) * 2020-04-09 2024-10-15 Verve Therapeutics, Inc. Base editing of ANGPTL3 and methods of using same for treatment of disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10257252A1 (de) * 2002-12-07 2004-08-12 Deere & Company, Moline Presse, insbesondere Rundballenpresse
ES2694018T3 (es) * 2007-07-02 2018-12-17 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el tratamiento y el diagnóstico del cáncer
WO2013012747A1 (fr) * 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Agents de fixation aux protéines rspo et leurs utilisations
CN104854132A (zh) * 2012-07-13 2015-08-19 昂考梅德药品有限公司 Rspo3结合剂及其用途
JP2016518328A (ja) * 2013-03-12 2016-06-23 キュアジェニックス インコーポレイテッド 癌治療のための化合物

Also Published As

Publication number Publication date
JP2018502833A (ja) 2018-02-01
MX2017006938A (es) 2017-08-24
WO2016090024A4 (fr) 2016-09-22
WO2016090024A3 (fr) 2016-08-04
CA2969401A1 (fr) 2016-06-09
WO2016090024A2 (fr) 2016-06-09
AU2015358506A1 (en) 2017-06-08
EP3226901A4 (fr) 2018-08-08
EP3226901A2 (fr) 2017-10-11
CN107708731A (zh) 2018-02-16
US20170266276A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
MA41555A (fr) Polythérapie pour le traitement du cancer
IL296080B1 (en) Method for treating cancer
MA45429A (fr) Polythérapie pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3322448A4 (fr) Nouvelle approche pour le traitement du cancer par immunomodulation
EP3621592A4 (fr) Polythérapies pour le traitement du cancer
MA41858A (fr) Polythérapie fgfr/pd-1 destinée au traitement du cancer
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
LT3119808T (lt) Antikūnų kompozicijos vėžio gydymui
EP3377068A4 (fr) Polythérapie comprenant des analogues de la quinolone tétracyclique pour le traitement du cancer
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3362066A4 (fr) Polythérapie pour le traitement de tumeurs malignes
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
MA47408A (fr) Traitement du cancer
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3375108A4 (fr) Traitement dewlan
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3503887A4 (fr) Combinaisons pour le traitement du cancer
PL3134119T3 (pl) Leczenie nowotworu
EP4067461C0 (fr) Procédé de réduction du point d'écoulement à efficacité élevée